Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 5/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 5/20 | 0.47 |
| ▸ | HRH2 | P25021 | 4/20 | 0.47 |
| ▸ | HRH1 | P35367 | 4/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28388624 | 0.94 | MMP2 (0.60) | ALDH1A1MAPTMMP2HRH3MMP3 | |
| SCHEMBL2779902 | 0.89 | HRH3 (0.53) | ALDH1A1MAPTMMP2HRH3MAOB | |
| SCHEMBL22645668 | 0.88 | HRH3 (0.54) | ALDH1A1MAPTMMP2HRH3MAOB | |
| SCHEMBL7986752 | 0.86 | ALDH1A1 (0.66) | ALDH1A1MAPTMMP2HRH3MAOB | |
| SCHEMBL9653965 | 0.84 | MMP2 (0.58) | MMP2HRH3MMP3HRH2HRH1 | |
| SCHEMBL5519875 | 0.84 | HRH3 (0.62) | ALDH1A1MAPTMMP2HRH3MAOB | |
| SCHEMBL7384498 | 0.84 | HRH3 (0.59) | ALDH1A1MAPTMMP2HRH3MAOB | |
| SCHEMBL9852404 | 0.83 | MMP3 (0.57) | MMP2HRH3MMP3HRH2HRH1 | |
| SCHEMBL535440 | 0.82 | MAOB (0.53) | ALDH1A1MAPTMMP2HRH3MAOB | |
| SCHEMBL7983991 | 0.82 | HRH3 (0.66) | ALDH1A1MAPTMMP2HRH3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | claimed |
| US-6903090-B2 | Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal | PFIZER (US) | 2005-06-07 | — | — | US | claimed |
| US-6828314-B2 | Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity | PFIZER | 2004-12-07 | — | — | US | claimed |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2003-12-04 | — | — | US | claimed |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | claimed |
| EP-1319005-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| EP-1319004-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | claimed |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2002-06-20 | — | — | US | claimed |
| WO-2002024700-A2 | SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| WO-2002024701-A2 | SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2020-03-17 | — | — | US | disclosed |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL SA (ES) | 2019-06-20 | — | — | US | disclosed |
| US-10034867-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2018-07-31 | — | — | US | disclosed |
| US-20170319557-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA, S.A. (ES) | 2017-11-09 | — | — | US | disclosed |
| CN-1166829-A | Iminooxymethylene anilides, process and intermediate products for preparing the same and pesticides containing the same | BASF AG (DE) | 1997-12-03 | — | — | CN | disclosed |
| CN-1161687-A | Phenylacetic acid alkyl esters | BASF AG (DE) | 1997-10-08 | — | — | CN | disclosed |
| WO-1997033874-A1 | PYRIMIDYL PHENYL AND BENZYL ETHERS, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION AND THEIR USE AS HERBICIDE | BASF AKTIENGESELLSCHAFT (DE) | 1997-09-18 | — | — | WO | disclosed |
| CN-1152908-A | Phenyl acetic acid derivatives, process and intermediate products for their production and agents containing them | BASF AG (DE) | 1997-06-25 | — | — | CN | disclosed |
| CN-1143361-A | Phenylacetic acid derivatives, their preparation and intermediates, and compositions containing them | BASF AG (DE) | 1997-02-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | ALDH1A1 610/4885MAPT 2666/4885MMP2 4096/4885 |
| US-10034867-B2 | Quinuclidine derivatives and medicinal compositions containing the same | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, OPRD1 | ALDH1A1 1663/4885MAPT 561/4885MMP2 4224/4885 |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | HTR5A, HTR1A, HTR4 | ALDH1A1 734/4885MAPT 2537/4885MMP2 4166/4885 |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRNB1, ARRB1 | ALDH1A1 1419/4885MAPT 2077/4885MMP2 3688/4885 |
| US-20170319557-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, OPRD1 | ALDH1A1 1556/4885MAPT 797/4885MMP2 4391/4885 |
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | CHRM3, QDPR, CHRM2 | ALDH1A1 1142/4885MAPT 1468/4885MMP2 2670/4885 |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | ALDH1A1 610/4885MAPT 2666/4885MMP2 4096/4885 |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | HTR5A, HTR1A, HTR4 | ALDH1A1 734/4885MAPT 2537/4885MMP2 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.